Shots:
- The collaboration will extend in 2022 for an additional 3yrs. Calico will lead R&D until 2025 & will advance projects into P-IIa through 2030 while AbbVie will support Calico in its early R&D efforts, following the completion of P-IIa studies, will get the option to manage late-stage development & commercial activities
- Both the companies will equally share costs & profits and each of them will contribute $500M to the collaboration. This marks the second extension of the collaboration originally established in 2014
- Since 2014, the collaboration has produced 20+ early-stage programs addressing disease across I-O and neurodegeneration and has yielded new insights into the biology of aging
Click here to read full press release/ article | Ref: Abbvie | Image: Wall Street Journal
The post AbbVie and Calico Expand its Existing Collaboration to Focus on Aging and Age-Related Diseases first appeared on PharmaShots.
